Detailed Mechanism Funding and Narrative

Years of mechanism: 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 9811
Country/Region: Mozambique
Year: 2015
Main Partner: Vanderbilt University
Main Partner Program: NA
Organizational Type: University
Funding Agency: HHS/CDC
Total Funding: $18,095,253 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $2,631,610
Care: TB/HIV (HVTB) $388,677
Care: Pediatric Care and Support (PDCS) $552,600
Testing: HIV Testing and Counseling (HVCT) $1,120,278
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $1,861,565
Treatment: Adult Treatment (HTXS) $10,271,756
Treatment: Pediatric Treatment (PDTX) $1,268,767
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 5,374
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 100,461
CARE_NEW Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 38,329
FN_THER Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period 2016 9,044
FN_THER Number of PLHIV who were nutritionally assessed and found to be clinically undernourished 2016 12,053
FPINT_SITE Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services 2016 172
FPINT_SITE Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment 2016 172
GEND_GBV Number of people receiving post-GBV care 2016 926
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2016 30,229
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2016 420,004
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 243
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 5,217
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 607
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 5,217
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2016 243
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2016 2,087
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2016 364
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2016 3,130
PMTCT_ARV Sum of New and Current disaggregates 2016 607
PMTCT_ARV Sum of New and Current disaggregates 2016 5,217
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2016 2,663
PMTCT_STAT By: Known positives at entry 2016 70
PMTCT_STAT By: Known positives at entry 2016 1,514
PMTCT_STAT By: Number of new positives identified 2016 173
PMTCT_STAT By: Number of new positives identified 2016 3,703
PMTCT_STAT Number of new ANC and L&D clients 2016 13,550
PMTCT_STAT Number of new ANC and L&D clients 2016 57,662
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 14,337
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 60,546
PMTCT_STAT Sum of Positives Status disaggregates 2016 243
PMTCT_STAT Sum of Positives Status disaggregates 2016 5,217
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2016 2,307
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2016 2,076
TB_SCREEN Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 5,374
TB_SCREEN Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 100,461
TX_CURR Age/Sex: <1 Female 2016 58
TX_CURR Age/Sex: <1 Female 2016 428
TX_CURR Age/Sex: <1 Male 2016 58
TX_CURR Age/Sex: <1 Male 2016 428
TX_CURR Age/Sex: 1-4 Female 2016 135
TX_CURR Age/Sex: 1-4 Female 2016 976
TX_CURR Age/Sex: 1-4 Male 2016 135
TX_CURR Age/Sex: 1-4 Male 2016 976
TX_CURR Age/Sex: 5-14 Female 2016 95
TX_CURR Age/Sex: 5-14 Female 2016 689
TX_CURR Age/Sex: 5-14 Male 2016 95
TX_CURR Age/Sex: 5-14 Male 2016 689
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2016 3,762
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2016 70,320
TX_CURR Sum of age/sex disaggregates 2016 4,186
TX_CURR Sum of Age/Sex disaggregations 2016 576
TX_NEW Aggregated Grouping by Age: <1 Male 2016 213
TX_NEW Aggregated Grouping by Age/Sex: <1 Female 2016 213
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2016 29,681
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2016 15,984
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2016 47,716
TX_NEW Pregnancy status 2016 3,130
TX_NEW Sum of Age/Sex disaggregates 2016 956
TX_NEW Sum of Aggregated Age/Sex disaggregates 2016 45,665
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2016 11,713
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2016 17,955
Cross Cutting Budget Categories and Known Amounts Total: $671,170
Motor Vehicles: Purchased $671,170